a Feasibility Study of iHD-SRT for BM

NCT ID: NCT06231186

Last Updated: 2024-04-10

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 35 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-03-15
• Study Completion Date: 2026-12-31

Brief Summary

Brain metastasis is the most challenging disease in the field of tumor treatment, with a median overall survival of only 1-2 months for untreated patients. Stereotactic radiotherapy (SRT) has the advantages of precise positioning, relatively concentrated dosage, shorter course, and lower toxicity. Several studies could effectively protect cognitive function and achieve better tumor control rate. Currently, it has gradually replaced WBRT as standard local treatment choice for brain metastases. SRT includes Stereotactic Radiosurgery (SRS) and Fractional Stereotactic Radiotherapy (fSRT). With the continuous updating of domestic radiation therapy equipment, the use of high-resolution multi leaf gratings enables the accuracy of fSRT based on linear accelerators to reach 0.5mm or even lower levels, and has gradually become one of the main choices for local treatment of a limited number of patients with brain metastases.

However, there is currently no prospective randomized controlled study data analyzing the clinical benefits of different segmentation and dosages of SRT. In retrospective data comparing different segmentation schemes, researchers found that higher BED was associated with better local control. However, the ASTRO guidelines recommend relatively conservative doses for SRT of brain metastases, especially as the lesion volume increases, and the recommended dose of BED10 for SRT was only 48 Gy (30 Gy/5 Fx). This is based on the consideration that higher radiation exposure will bring a higher risk of radiation-induced brain necrosis. However, with the continuous updates of SRT treatment equipment and technology, existing technologies can achieve higher dose coverage for more brain metastases while meeting the normal tissue limit. Therefore, this study conducted a prospective intervention study to explore the feasibility and safety of optimizing SRT dosage based on normal tissue tolerance for the treatment of brain metastases, in order to further improve the therapeutic effect of intracranial lesions with brain metastases.

This study is designed as a single arm open prospective study, assuming that under this treatment regimen, the proportion of patients with lesion prescription dose BED10>50 Gy is 90%, and the incidence of radiation-induced brain necrosis within 1 year is 8.5%. The planned enrollment period is 2 years and follow-up period is 1 year. A total of 35 people need to be enrolled.

Conditions

Brain Metastases, Adult; Stereotactic Radiotherapy

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

iHD-SRT

isotoxic high dose SRT

Group Type: EXPERIMENTAL

iHD-SRT

Intervention Type: RADIATION

received isotoxic individualized fSRT, with BED 10\>50Gy and \<100Gy, and strict OAR limits

Interventions

iHD-SRT

received isotoxic individualized fSRT, with BED 10\>50Gy and \<100Gy, and strict OAR limits

Intervention Type: RADIATION

Eligibility Criteria

Inclusion Criteria

• Ability to understand and willingness to participate the research and sign the consent form
• ECOG PS 0-2
• The primary or metastatic lesion was confirmed by pathological histology as a malignant tumor
• Head MRI diagnosis of brain metastasis with measurable lesions and technically feasible SRT (no more than 15 in number and 20cc in volume)
• Estimated survival time ≥ 3 months

Exclusion Criteria

• Diffuse brain metastases, or combined with meningeal metastases, or technically difficult to perform SRT
• With severe internal medicine complications or absolute contraindications for radiotherapy
• other sufficient reasons to be unqualified, such as potential non-compliance with the clinical protocol, etc

• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Ruijin Hospital

OTHER

Sponsor Role: lead

Responsible Party

JIAYI CHEN

Prof

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Jiayi Chen

Role: PRINCIPAL_INVESTIGATOR

Ruijin Hospital

Locations

Ruijin Hospital

Shanghai, Shanghai Municipality, China

Site Status: RECRUITING

Countries

China

Central Contacts

Dan Ou, MD

Role: CONTACT

od12341@rjh.com.cn

8618801970632

Facility Contacts

Dan Ou

Role: primary

od12341@rjh.com.cn

+8618801970632

Other Identifiers

2024（006）

Identifier Type: -

Identifier Source: org_study_id